{"id":"https://openalex.org/W2590768171","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.7295","title":"Phase II trial evaluating combination, weekly gemcitabine and docetaxel in progressive, chemotherapy-exposed NSCLC: Preliminary results of OPN 003","display_name":"Phase II trial evaluating combination, weekly gemcitabine and docetaxel in progressive, chemotherapy-exposed NSCLC: Preliminary results of OPN 003","publication_year":2005,"publication_date":"2005-06-01","ids":{"openalex":"https://openalex.org/W2590768171","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.7295","mag":"2590768171"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2005.23.16_suppl.7295","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.7295","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.7295","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5102816495","display_name":"C. Huang","orcid":"https://orcid.org/0000-0003-3601-2348","observed_orcids":["https://orcid.org/0000-0003-3601-2348"]},"institutions":[{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. H. Huang","raw_affiliation_strings":["Kansas Univ Medcl Ctr, Overland Park, KS; Fox Chase Cancer Ctr, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kansas Univ Medcl Ctr, Overland Park, KS; Fox Chase Cancer Ctr, Philadelphia, PA","institution_ids":["https://openalex.org/I1289437631"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090256464","display_name":"Corey Jay Langer","orcid":"https://orcid.org/0000-0002-8483-6811","observed_orcids":["https://orcid.org/0000-0002-8483-6811"]},"institutions":[{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. J. Langer","raw_affiliation_strings":["Kansas Univ Medcl Ctr, Overland Park, KS; Fox Chase Cancer Ctr, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kansas Univ Medcl Ctr, Overland Park, KS; Fox Chase Cancer Ctr, Philadelphia, PA","institution_ids":["https://openalex.org/I1289437631"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030855310","display_name":"Michael Mark Millenson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. M. Millenson","raw_affiliation_strings":["Kansas Univ Medcl Ctr, Overland Park, KS; Fox Chase Cancer Ctr, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kansas Univ Medcl Ctr, Overland Park, KS; Fox Chase Cancer Ctr, Philadelphia, PA","institution_ids":["https://openalex.org/I1289437631"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061365371","display_name":"Eric Jeffrey Sherman","orcid":"https://orcid.org/0000-0002-4960-4783","observed_orcids":["https://orcid.org/0000-0002-4960-4783"]},"institutions":[{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E. Sherman","raw_affiliation_strings":["Kansas Univ Medcl Ctr, Overland Park, KS; Fox Chase Cancer Ctr, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kansas Univ Medcl Ctr, Overland Park, KS; Fox Chase Cancer Ctr, Philadelphia, PA","institution_ids":["https://openalex.org/I1289437631"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112768856","display_name":"J. Alex Seldomridge","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Seldomridge","raw_affiliation_strings":["Kansas Univ Medcl Ctr, Overland Park, KS; Fox Chase Cancer Ctr, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kansas Univ Medcl Ctr, Overland Park, KS; Fox Chase Cancer Ctr, Philadelphia, PA","institution_ids":["https://openalex.org/I1289437631"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037357362","display_name":"Jessie Schol","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Schol","raw_affiliation_strings":["Kansas Univ Medcl Ctr, Overland Park, KS; Fox Chase Cancer Ctr, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kansas Univ Medcl Ctr, Overland Park, KS; Fox Chase Cancer Ctr, Philadelphia, PA","institution_ids":["https://openalex.org/I1289437631"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090472587","display_name":"Andr\u00e9 Rogatko","orcid":"https://orcid.org/0000-0001-8935-8890","observed_orcids":["https://orcid.org/0000-0001-8935-8890"]},"institutions":[{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Rogatko","raw_affiliation_strings":["Kansas Univ Medcl Ctr, Overland Park, KS; Fox Chase Cancer Ctr, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kansas Univ Medcl Ctr, Overland Park, KS; Fox Chase Cancer Ctr, Philadelphia, PA","institution_ids":["https://openalex.org/I1289437631"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5061100035","display_name":"Joseph Treat","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Treat","raw_affiliation_strings":["Kansas Univ Medcl Ctr, Overland Park, KS; Fox Chase Cancer Ctr, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kansas Univ Medcl Ctr, Overland Park, KS; Fox Chase Cancer Ctr, Philadelphia, PA","institution_ids":["https://openalex.org/I1289437631"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1289437631"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"23","issue":"16_suppl","first_page":"7295","last_page":"7295"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.8241999745368958,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.8241999745368958,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.1720000058412552,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9279999732971191},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.6420000195503235},{"id":"https://openalex.org/keywords/salvage-chemotherapy","display_name":"salvage chemotherapy","score":0.8610000014305115},{"id":"https://openalex.org/keywords/weekly-docetaxel","display_name":"weekly docetaxel","score":0.8939999938011169},{"id":"https://openalex.org/keywords/gemcitabine","display_name":"gemcitabine","score":0.9120000004768372},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.7289999723434448},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6759999990463257},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.9169999957084656},{"id":"https://openalex.org/keywords/response-rate","display_name":"response rate","score":0.6710000038146973},{"id":"https://openalex.org/keywords/survival","display_name":"survival","score":0.6480000019073486},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.6510000228881836},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9670000076293945},{"id":"https://openalex.org/keywords/paclitaxel","display_name":"paclitaxel","score":0.7279999852180481}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9420620203018188},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.9233639240264893},{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.9129761457443237},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.687979519367218},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6415835618972778},{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.6082137227058411},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.5386229753494263},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5047041177749634},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.49689939618110657},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.4894086420536041},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3538397550582886},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3399896025657654},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.06313759088516235}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2005.23.16_suppl.7295","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.7295","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.7295","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.6800000071525574}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2308557320","https://openalex.org/W2068905464","https://openalex.org/W2202375773","https://openalex.org/W2003291927","https://openalex.org/W2256514287","https://openalex.org/W2315587357","https://openalex.org/W2014528870","https://openalex.org/W2591142166","https://openalex.org/W2604515904","https://openalex.org/W2063487050"],"abstract_inverted_index":{"7295":[0],"Background:":[1],"Docetaxel":[2],"is":[3,156,249,279],"the":[4,28,41,111,119,273],"first":[5],"FDA":[6],"approved":[7],"systemic":[8,51],"agent":[9],"for":[10],"second":[11],"line":[12],"therapy":[13],"(Tx)":[14],"of":[15,44,113],"NSCLC.":[16],"In":[17,71,110],"single":[18],"institution":[19],"consortium":[20],"studies,":[21],"gemcitabine":[22,88,120,240,271],"has":[23],"demonstrated":[24],"similar":[25],"activity":[26,286],"in":[27,38,40,197,208,213,236,242,272],"salvage":[29,42,274],"setting.":[30],"We":[31],"therefore":[32],"opted":[33],"to":[34,59,124,160,188,253,261],"assess":[35],"both":[36],"agents":[37],"combination":[39],"Tx":[43],"patients":[45,135],"(pts)":[46],"who":[47],"had":[48],"received":[49,101,183,227],"prior":[50,61,184,191],"chemotherapy.":[52],"Methods:":[53],"Eligibility":[54],"stipulated":[55],"advanced":[56],"NSCLC,":[57],"exposure":[58],"one":[60],"platinum":[62],"based":[63],"regimen,":[64],"PS":[65,165],"0\u20131,":[66],"and":[67,87,93,103,108,129,148,211,239,258,270,287],"adequate":[68],"physiologic":[69],"indices.":[70],"radiation-na\u00ef":[72],"ve":[73],"pts,":[74,140,199,210],"docetaxel":[75,269],"was":[76,122],"dosed":[77],"at":[78,89],"40mg/m2":[79,102],"days":[80,91,106,127],"1":[81,92,107,125,128,243],"&":[82],"8":[83,94,181,237],"q":[84,95],"3":[85,96,115],"wks,":[86],"800mg/m2":[90],"wks.":[97],"RT":[98],"exposed":[99],"pts":[100,225],"600mg/m2":[104],"respectively":[105],"8.":[109,130],"absence":[112],"grade":[114],"or":[116,294,297],"4":[117,177,198],"neutropenia/thrombocytopenia,":[118],"dose":[121],"escalated":[123],"g/m2":[126],"Results:":[131],"To":[132],"date,":[133],"25":[134],"have":[136,221],"been":[137,222],"enrolled.":[138],"17":[139],"(8":[141],"men,":[142],"9":[143],"women)":[144],"enrolled":[145],"between":[146],"6/02":[147],"1/04,":[149],"are":[150,164],"fully":[151],"evaluable.":[152],"The":[153,245],"median":[154,259,289],"age":[155],"61":[157,215],"(range,":[158],"44":[159],"79).":[161],"12":[162],"(71%)":[163],"1.":[166,214],"All":[167],"were":[168],"previously":[169],"treated":[170],"with":[171,175,179,282],"carboplatin,":[172],"15":[173],"(88%)":[174],"paclitaxel,":[176],"(24%)":[178],"docetaxel.":[180],"(47%)":[182,238],"RT,":[185],"6":[186,224,229,264],"(35%)":[187,226],"brain.":[189],"Other":[190,307],"exposures":[192],"included":[193,234],"erolotinib":[194],"(versus":[195],"placebo)":[196],"CP":[200],"547,":[201],"632,":[202],"an":[203],"experimental":[204],"oral":[205],"angiogenesis":[206],"inhibitor":[207],"2":[209,256],"bevacizumab":[212],"cycles":[216],"(median":[217],"3,":[218],"range":[219],"2\u201310)":[220],"administered.":[223],"\u2265":[228],"cycles.":[230],"Grade":[231],"3/4":[232],"toxicity":[233],"neutropenia":[235],"pneumonitis":[241],"(6%).":[244],"confirmed":[246],"response":[247],"rate":[248],"22%.":[250],"Median":[251],"time":[252],"progression":[254],"exceeds":[255,263],"mos,":[257],"survival":[260],"date":[262],"mos.":[265],"Conclusions:":[266],"Combination":[267],"weekly":[268],"setting":[275],"post":[276],"carboplatin-taxane":[277],"failure":[278],"well":[280],"tolerated,":[281],"acceptable":[283],"toxicity,":[284],"clear":[285],"promising":[288],"survival.":[290],"Author":[291],"Disclosure":[292],"Employment":[293],"Leadership":[295],"Consultant":[296],"Advisory":[298],"Role":[299],"Stock":[300],"Ownership":[301],"Honoraria":[302],"Research":[303],"Funding":[304],"Expert":[305],"Testimony":[306],"Remuneration":[308],"Aventis":[309],"AstraZeneca,":[310,319],"Aventis,":[311,320],"Bristol-Myers":[312,321],"Squibb,":[313,322],"Genentech,":[314,323],"ImClone,":[315],"Novartis":[316],"Lilly":[317,324],"Oncology":[318],"Oncology,":[325],"Pfizer":[326]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2017-03-03T00:00:00"}